SubsidieMeestersHormone-free solution for vaginal atrophy
AVeta is a hormone-free medical device providing safe, affordable, and effective self-administered therapy for women suffering from vaginal atrophy, enhancing their quality of life.
Projectdetails
Introduction
Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts the quality of life, relationships, everyday activities, and confidence of women sufferers. It is associated with thinning, drying, and inflammation of the vaginal tissue.
Prevalence
It is experienced by 80% of all women globally and is the most common symptom of menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy, and the cancer-blocker drugs they take further exacerbate symptoms of VA.
Current Treatment Options
Current treatment options for VA, primarily pharmaceuticals, are either ineffective or poorly tolerated. In the EU and US, 3.6 million patients with VA reject existing treatments.
AVeta Solution
AVeta is a medical device delivering the only hormone-free, affordable, and safe targeted therapy for all women suffering from VA. The solution is based on the pathophysiology of wound healing and will be prescribed by a clinician in an outpatient setting. Women will self-administer the therapy monthly at home.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.814.567 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- AVETA MEDICAL LIMITEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary IncontinenceDeveloping UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity. | EIC Accelerator | € 2.499.999 | 2023 | Details |
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platformWomed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain. | EIC Accelerator | € 2.493.809 | 2024 | Details |
Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg UlcersEnVena is a groundbreaking device designed to mimic the body's healing response, providing effective treatment for venous leg ulcers and addressing the limitations of current compression bandaging. | EIC Accelerator | € 2.497.614 | 2022 | Details |
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitisGedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.
VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health.
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary Incontinence
Developing UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity.
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform
Womed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain.
Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg Ulcers
EnVena is a groundbreaking device designed to mimic the body's healing response, providing effective treatment for venous leg ulcers and addressing the limitations of current compression bandaging.
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis
Gedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
ArvinaArvina ontwikkelt een synthetisch biomateriaal voor effectieve borstreconstructie, ter verbetering van de levenskwaliteit van borstkankerpatiënten. | 1.1 - Het ve... | € 482.195 | 2023 | Details |
Dan Jing WuVivArt-X ontwikkelt een innovatief synthetisch biomateriaal voor veiligere en effectievere borstreconstructie na borstamputatie. | Mkb-innovati... | € 19.320 | 2023 | Details |
Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic ResponseSWEATPATCH aims to develop a non-invasive, real-time monitoring system using sweat VOCs to personalize breast cancer treatment and improve patient outcomes through innovative technology. | EIC Pathfinder | € 2.670.933 | 2024 | Details |
Valorization of Lactobacilli and their Antimicrobial Peptides for Reproductive and Intimate Health EnhancementThe VALERIE project aims to purify and characterize antimicrobial compounds from vaginal lactobacilli to develop innovative treatments against antibiotic-resistant pathogens. | ERC Proof of... | € 150.000 | 2025 | Details |
Een Total Vaccine Delivery Solution als preventie van én therapie voor HPV-geïnduceerde kanker.uPATCH en MyLife ontwikkelen een innovatieve vaccinatiepatch met applicator om HPV-infecties wereldwijd te bestrijden en vaccinatie toegankelijker te maken, zonder prikangst. | Mkb-innovati... | € 350.000 | 2022 | Details |
Arvina
Arvina ontwikkelt een synthetisch biomateriaal voor effectieve borstreconstructie, ter verbetering van de levenskwaliteit van borstkankerpatiënten.
Dan Jing Wu
VivArt-X ontwikkelt een innovatief synthetisch biomateriaal voor veiligere en effectievere borstreconstructie na borstamputatie.
Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response
SWEATPATCH aims to develop a non-invasive, real-time monitoring system using sweat VOCs to personalize breast cancer treatment and improve patient outcomes through innovative technology.
Valorization of Lactobacilli and their Antimicrobial Peptides for Reproductive and Intimate Health Enhancement
The VALERIE project aims to purify and characterize antimicrobial compounds from vaginal lactobacilli to develop innovative treatments against antibiotic-resistant pathogens.
Een Total Vaccine Delivery Solution als preventie van én therapie voor HPV-geïnduceerde kanker.
uPATCH en MyLife ontwikkelen een innovatieve vaccinatiepatch met applicator om HPV-infecties wereldwijd te bestrijden en vaccinatie toegankelijker te maken, zonder prikangst.